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Abstract
AIM: To investigate whether matrix metalloprotein-
ases-9 (MMP-9) or trypsinogens could serve as his-
tological markers for an aggressive disease course in 
pediatric ulcerative colitis (UC).
METHODS: We identified 24 patients with pediatric 
onset (≤ 16 years) UC who had undergone surgery 
during childhood/adolescence a median of 2.1 years 
(range 0.1-7.4 years) after the diagnosis (between 
1990 and 2008) in Children’s Hospital, Helsinki, Fin-
land. We also identified 27 conservatively treated UC 
patients and matched them based on their age at the 
time of diagnosis and follow-up at a median of 6 years 
(range 3-11 years) to serve as disease controls. Twen-
ty children for whom inflammatory bowel disease (IBD) 
had been excluded as a result of endoscopy served as 
non-IBD controls. Colon biopsies taken by diagnostic 
endoscopy before the onset of therapy were stained 
using immunohistochemistry to study the expression of 
MMP-9, trypsinogen-1 (Tryp-1), Tryp-2, and a trypsin 
inhibitor (TATI). The profiles of these proteases and 
inhibitor at diagnosis were compared between the sur-
gery group, the conservatively treated UC patients and 
the non-IBD controls.
RESULTS: The proportions of Tryp-1 and Tryp-2 posi-
tive samples in the colon epithelium and in the inflam-
matory cells of the colon stroma were comparable 
between the studied groups at diagnosis. Interestingly, 
the immunopositivity of Tryp-1 (median 1; range 0-3) 
was significantly lower in the epithelium of the colon 
in the pediatric UC patients undergoing surgery when 
compared to that of the conservatively treated UC pa-
tients (median 2; range 0-3; P  = 0.03) and non-IBD 
controls (median 2; range 0-3; P  = 0.04). For Tryp-2, 
there was no such difference. In the inflammatory cells 
of the colon stroma, the immunopositivities of Tryp-1 
and Tryp-2 were comparable between the studied 
groups at diagnosis. Also, the proportion of samples 
positive for TATI, as well as the immunopositivity, was 
comparable between the studied groups in the colon 
epithelium. In the stromal inflammatory cells of the 
colon, TATI was not detected. In UC patients, there 
were significantly more MMP-9 positive samples and 
a higher immunopositivity in the stromal inflamma-
tory cells of the colon when compared to the samples 
from the non-IBD patients (P  = 0.006 and P  = 0.002, 
respectively); the immunopositivity correlated with the 
histological grade of inflammation (95%CI: 0.22-0.62; 
P  = 0.0002), but not with the other markers of active 
disease. There were no differences in the immunoposi-
tivity or in the proportions of MMP-9 positive samples 
when examined by epithelial staining. The staining 
profiles in the ileal biopsies were comparable between 
the studied groups for all of the studied markers.
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CONCLUSION: For pediatric UC patients who require 
surgery, the immunopositivity of Tryp-1 at diagnosis is 
lower when compared to that of patients with a more 
benign disease course.
© 2013 Baishideng. All rights reserved.
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Core tip: The risk factors for aggressive pediatric ulcer-
ative colitis (UC) were studied in 24 patients who had 
undergone surgery by staining diagnostic tissue sam-
ples for matrix metalloproteinase-9 and trypsinogen-1 
(Tryp-1) and Tryp-2, as well as a trypsin inhibitor. In 
the UC group, there were significantly more samples 
that were matrix metalloproteinase-9 positive in com-
parison to the samples from non-inflammatory bowel 
disease patients. UC patients undergoing colectomy 
showed lower immunopositivity of Tryp-1 in the colon 
epithelium in their diagnostic biopsies when compared 
to that of conservatively treated patients and non-
inflammatory bowel disease patients. The discovery of 
a low trypsinogen level at diagnosis warrants further 
study.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a common name 
for Crohn’s disease (CD), ulcerative colitis (UC), and 
unclassified colitis. Some patients may have only one 
episode of  active disease and remain in remission for the 
rest of  their lives, while others will suffer from a relaps-
ing or continuously active disease and require colecto-
my[1-3]. The studied risk factors for an aggressive disease 
course (steroid dependency[4], pancolitis[4,5], extraintestinal 
manifestations[5], severe disease at diagnosis[6], or disease 
extension from the primary site of  the active disease) are 
related to the clinical presentation and thus it is impos-
sible to foresee the phenotype of  the disease at diagnosis.
Since many pediatric UC patients present with aggres-
sive disease during their disease course, it would be benefi-
cial to find biomarkers that at the onset of  disease could 
distinguish patients with complicated disease behavior 
and a high risk for surgery from those with a more benign 
course. The current opinion, however, is that immunosup-
pressive treatment is needed for a patient with a compli-
cated disease. If  it was possible to recognize an aggressive 
disease with biomarkers in the early disease phase, then 
such patients could be introduced to immunosuppres-
sive treatment aiming to improve the disease outcome. 
Previous pediatric data show the benefits of  immunosup-
pressive treatment[7-9], although biological treatment with 
a tumor necrosis factor-α (TNF-α) antagonist has, disap-
pointingly, not reduced the surgery rates[10].
Matrix metalloproteinases (MMPs), a family of  24 
zinc-dependent enzymes, comprise a group of  protein-
ases[11] that degrade the extracellular matrix and basement 
membrane proteins in tissue remodeling processes both 
in normal and in pathological conditions[11]. In IBD the 
most abundantly expressed MMP is MMP-9[12]. Previous-
ly, we have shown that the immunopositivity of  MMP-9 
in the colon decreases after TNF-α antagonist treatment 
in adult CD[13]. Trypsinogens are serine proteases that are 
capable of  degrading extracellular matrix proteins and 
the pro-forms of  acute phase reaction proteins[14], such 
as TNF-α, which cause damage to the mucosal barrier 
and UC-like inflammation[15]. The exact role of  trypsino-
gens in IBD for the most part remains unknown, but it is 
known that trypsins activate promatrix metalloproteinases 
(proMMPs), especially the IBD-related proMMP-9[16-19]. 
Tumor associated trypsin inhibitor (TATI), also called 
pancreatic secretory trypsin inhibitor[20], inhibits trypsin 
in a 1:1 molar ratio[21]. Extrapancreatically secreted TATI 
is assumed to play additional roles in ulcer healing and 
tissue regeneration[22]. TATI also takes part in prevent-
ing the excessive digestion of  gastrointestinal (GI) mu-
cus[22,23]. As with trypsinogens, the role of  TATI in IBD-
related inflammation is mostly unknown.
Matrix and serine proteases may be regarded as “regu-
lators” of  the barrier and inflammation cascade of  the 
gut[14]. Accordingly, we hypothesized that the presence of  
expression of  such proteases would be associated with 
the severity of  the course of  IBD. The hypothesis was 
tested by comparing the results of  immunohistochemical 
stainings with MMP-9, trypsinogen-1 (Tryp-1), Tryp-2, 
and TATI on the biopsy material of  pediatric patients 
who underwent surgery vs conservatively treated patients 
and subjects without IBD.
MATERIALS AND METHODS
Patients and controls
We reviewed all pediatric onset (≤ 16 years old) UC 
patients from the IBD patient registry of  Children’s Hos-
pital, Helsinki University Central Hospital who had been 
diagnosed between 1990 and 2008. From this database, 
we identified 24 UC patients who had undergone sur-
gery (time from diagnosis to surgery, maximum 7 years) 
and 27 conservatively treated disease controls. The latter 
group had been diagnosed at the same age as the oper-
ated patients and the follow-up took place within the pe-
riod of  time that had elapsed between the diagnosis and 
the surgery in the index case. None of  the disease con-
trols underwent an operation during follow-up (median 
6 years). All of  the patients had undergone diagnostic 
ileocolonoscopy and upper gastrointestinal endoscopy, 
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and during follow-up the diagnosis remained consistent 
for the UC patients. Table 1 presents the background 
data of  the study groups. The data on the indications and 
type of  surgical therapy of  the patients is shown in Table 
2. Twenty children who had undergone ileocolonoscopy 
with biopsies and who did not suffer from IBD served 
as non-IBD controls. The indications for endoscopy in 
these children were as follows: suspected IBD (n = 12), 
abdominal pain (n = 4), colorectal bleeding (n = 3), and 
pancreatic insufficiency (n = 1).
For all of  the patients and controls, tissue samples 
from the diagnostic ileocolonoscopy (colonic and ileal 
biopsies) were stained with immunohistochemistry to test 
for MMP-9, Tryp-1, Tryp-2, and TATI antibodies (see 
below). Based on the patient records, we reviewed the 
laboratory values of  albumin, C-reactive protein (CRP), 
the erythrocyte sedimentation rate (ESR), the white 
blood cell count (WBC), and the haemoglobin at the time 
of  the ileocolonoscopy.
Inflammatory score and disease severity
The disease was considered to be acute and severe if  the 
patient required hospitalization at diagnosis and the PU-
CAI score was over 65[24]. The endoscopic distribution of  
the disease at the time of  the diagnostic colonoscopy was 
scored as 0, indicating no inflammation, as 1 for procti-
tis, as 2 for left-sided colitis, and as 3 for pancolitis. The 
degree of  histological inflammation was recorded based 
on the primary diagnostic histological examination re-
ports provided by experienced pathologists. The samples 
were graded according to the presence of  ulceration, the 
frequency of  acute and chronic inflammatory cells, crypt 
distortion, and goblet cell depletion recorded on a scale 
of  0 to 2 (0 no inflammation, 1 mild inflammation, 2 
moderate to severe inflammation) (modified from Beattie 
et al[25]). The presence of  backwash ileitis in the diagnostic 
ileocolonoscopy was also recorded.
Immunohistochemistry 
Formalin-fixed, paraffin-embedded tissue sections (4-μm) 
were deparaffinized in xylene and rehydrated in graded 
concentrations of  ethanol and water. To block endogenous 
peroxidase activity, the sections were treated with 0.3% 
Dako REAL Peroxidase-Blocking Solution (DAKO, Glos-
trup, Denmark) for 5 min. For the antigen retrieval tissue, 
the sections were treated in the pretreatment module of  
the Autostainer (LabVision UK Ltd) in a Tris-HCl buffer 
(pH 8.5) for 20 min at 98 ℃ (Tryp-1 and MMP), a 0.1% 
pepsin solution for 15 min at 37 ℃ (Tryp-2), or a 0.01% 
trypsin solution for 30 min at 37 ℃ (TATI). After pretreat-
ment, a Lab Vision Autostainer TM 480 (LabVision, Fre-
mont, CA, United States) was used for immunohistochem-
istry. The sections were incubated with antibodies against 
Tryp-1 at a dilution of  1:500 (MAB 1482, Chemicon, 
Temecula, CA, United States), against MMP-9 (RB-1539-
PO, LabVision Fremont, CA) at a dilution of  1:1000, and 
against Tryp-2 (8F7)[26] and TATI (6E8)[27] at dilutions of  
1:200 and 1:500, respectively. The incubation times were 
one hour for Tryp-1, MMP-9, and TATI and overnight for 
Tryp-2. Subsequently, the sections were incubated with a 
peroxidase-conjugated Dako REAL EnVision/HRP, Rab-
bit/Mouse (ENV) reagent for 30 min. The final visualiza-
tion was performed by incubating the sections in DAKO 
REAL DAB+ Chromogen for 10 min. Between the stain-
ing steps, the slides were washed with 0.04% PBS. Mayer’s 
hematoxylin was used for counterstaining. Finally, the sec-
tions were rinsed in tap water for 10 min and mounted in 
an aqueous mounting medium (Aguamount, BDH, Poole, 
United Kingdom). As positive controls, we used formalin-
fixed, paraffin-embedded sections of  pancreatic papillary 
carcinoma (Tryp-1), pancreatic adenocarcinoma (Tryp-2 
and TATI), and ventricular adenocarcinoma (MMP-9). A 
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  Patient groups Surgery Disease Non-IBD
controls controls
  No. of patients (male)     24 (11)     27 (15)      20 (10)
  Age at diagnosis (yr),
  median (range)
 13.1 (3.1-16.0)  12.1 (2.8-16.6)   13.5 (2.7-16.8)
  Time from diagnosis to 
  surgery (yr), 
  median (range) 
   2.1 (0.1-7.4)       -        -
  Follow-up (yr),
  median (range)
       -    6.3 (2.8-10.7)     1.0 (0.0-4.0)
  Endoscopic disease extension
     Proctitis       0       1        -
     Left-sided colitis       9       6        -
     Pancolitis     15     20        -
     No inflammation       -       -      20
  Histological inflammation1
     No inflammation       -       -      18
     Mild       6     10        1
     Moderate to severe     18     17        -
  Laboratory markers, median (range)
     Hb (g/L)   112 (86-135)   116 (86-140) 131.0 (93-153)
     ESR (mm/h)     25 (7-61)     22 (7-63)        8 (2-23)
     CRP (mg/L)     20 (< 3-92)       9 (< 5-36)     < 3 (< 3-< 5)
     WBC (E9/L)    9.6 (6.7-26.3)    7.5 (4.1-15.9)     5.1 (3.0-16.3)
     Alb (g/L)  34.6 (28.0-40.0)  36.2 (23.6-42.6)   42.3 (39.8-47.2)
Table 1  Clinical data of the pediatric study groups at the 
time of diagnostic endoscopy
1For the non-inflammatory bowel disease (IBD) controls, data were miss-
ing in one case. Alb: Albumin; CRP: C-reactive protein; ESR: Erythrocyte 
sedimentation rate; Hb: Haemoglobin; WBC: White blood cell count.
  Age at first surgery (yr), median (range) 15.3 (5.5-19.8)
  Time from diagnosis to surgery (yr), median (range)   2.1 (0.1-6.6)
  Indication for primary operation
     Stricture      1 (perianal)
     Refractory disease to medication    20
        Steroid-dependency    18
        No response to TNF-alpha antagonist      2
     Fulminant colitis      3
  Primary operation
     Colectomy (IRA)      1
     Proctocolectomy (IPAA)    23
Table 2  Surgical data for 24 pediatric patients with ulcerative 
colitis
IPAA: Ileal pouch anal anastomosis; IRA: Ileorectal anastomosis; TNF: Tu-
mor necrosis factor.
Piekkala M et al . Proteases in pediatric UC at diagnosis
3275 June 7, 2013|Volume 19|Issue 21|WJG|www.wjgnet.com
exact test were performed to investigate the significance of  
the association between the level of  immnopositivities and 
the clinical markers. A P < 0.05 was considered significant.
RESULTS
Disease severity and distribution and medication
The endoscopic distribution of  inflammation was com-
parable between the UC groups (P = 0.7). During the 
diagnostic biopsies, we detected mild inflammation in 
16 of  51 (31%) and moderate to severe inflammation in 
35 of  51 UC patients (69%), without major differences 
between surgical and conservative groups (P = 0.2). Of  
the 24 patients requiring surgery (median two years after 
diagnosis), 46% (n = 11) had an acute severe disease at 
diagnosis. This was significantly more than in the disease 
controls (15%, n = 4) (P = 0.03). In total, 15 of  51 UC 
patients (30%) had an acute severe disease at diagnosis 
(73% of  them underwent surgery).
Staining results in the colon
Table 3 shows the proportions of  Tryp-1, Tryp-2, TATI, 
and MMP-9 positive samples, the median levels of  im-
munopositivity, and the P values when comparing the 
proportions of  positive samples and the level of  immu-
nopositivity between the surgery group and the conserva-
tively treated or non-IBD groups.
Tryp-1: Tryp-1 was stained in the colon epithelium and 
tissue sample without a primary antibody served as a nega-
tive control during each staining.
Interpretation of staining results
The immunohistochemical specimens were scored inde-
pendently by two investigators (Piekkala M and Hagström 
J) in a semi-quantitative fashion under a light-field micro-
scope at × 100 magnification using a marking and stain-
ing immunopositivity scale. This was done as follows: 
negative immunoreactivity was scored as 0, a diffuse weak 
positivity was scored as 1, a moderately positive or focally 
strongly positive immunopositivity was scored as 2, and 
a homogeneously strong immunopositivity was scored as 
3 (modified from Böckelman et al[28]). An experienced pa-
thologist (Hagström J) confirmed the identity of  the cell 
types producing each Tryp-1, Tryp-2, TATI, or MMP-9.
Ethics
The National Supervisory Authority for Welfare and 
Health gave its permission for use of  the tissue samples. 
In accordance with Finnish regulations, no informed 
consent is required for this kind of  study. 
Statistical analysis
Because of  the small number of  patients, the non-para-
metric Mann-Whitney’s test and Kruskal-Wallis test were 
used to compare the significance of  the differences in the 
level of  immunopositivities between the studied groups. 
An independent samples t test (Spearman), and Fisher’s 
Surgery 
(n  = 24)
Conservative treatment 
controls (n  = 27)
Non-IBD controls 
(n  = 20)
P  value 
Surgery vs  conservative treatment controls
P  value 
Surgery vs  non-IBD controls
  Number of positive samples  n (%)
     Tryp-1
        Epithelium    13 (57)             19 (76)           15 (79) 0.22 0.19
        Stroma; inflammatory cells    11 (48)               8 (32)             5 (26) 0.38 0.21
     Tryp-2
        Epithelium    21 (95)             21 (81)           18 (95) 0.20 0.22
     TATI
        Epithelium    18 (78)             24 (92)           15 (75) 0.23 1.00
     MMP-9
        Epithelium      4 (18)               2 (8)             0 (0) 0.40 0.17
        Stroma; inflammatory cells    11 (50)             12 (48)             1 (5) 1.00    0.0061
  Median immunopositivity
     Tryp-1
        Epithelium      1.0               2.0             2.0  0.032  0.042
        Stroma; inflammatory cells      0.0               0.0             0.0 0.16 0.10
     Tryp-2
        Epithelium      1.0               1.0             1.0 0.56 0.38
     TATI   
        Epithelium      1.0               1.0             1.0 0.81 0.97
     MMP-9
        Epithelium      0.0               0.0             0.0 0.33 0.17
        Stroma; inflammatory cells      0.5               0.0             0.0 0.89    0.0033
Table 3  Semi-quantitative immunopositivity (score 0 to 3) and number of positive samples in the diagnostic colonic tissue samples 
of pediatric ulcerative colitis patients and non inflammatory bowel disease patients
1Both UC patient groups had significantly more positively stained inflammatory cells in their colonic epithelium when compared to the non-IBD controls; 
2The patients who had undergone surgery had significantly lower immunopositivity when compared to the conservatively treated and non-IBD controls; 
3Both UC patient groups had significantly higher immunopositivity when compared to the non-IBD controls. IBD: Inflammatory bowel disease; UC: Ulcer-
ative colitis; TATI: Trypsin inhibitor; Tryp-2: Trypsinogen-2; MMP-9: Matrix metalloproteinase-9.
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in the inflammatory cells of  the stroma. The staining of  
Tryp-1 was granular. The immunopositivity in the colon 
epithelium was significantly lower in the samples from 
the surgery group (Figure 1A) when compared to that 
of  the conservatively treated (Figure 1B) and non-IBD 
controls (Table 3). No difference in the immunopositivity 
of  the colon epithelium was found between the conser-
vatively treated and non-IBD controls. The proportion 
of  positive samples and the level of  immunopositivity in 
the inflammatory cells of  the stroma were similar in the 
studied groups (Table 3).
Tryp-2: Tryp-2 was stained in the epithelium. All of  the 
samples, regardless of  the study group, had the same 
level of  Tryp-2 immunopositivity in the inflammatory 
cells of  the colon stromal tissue (Figure 2A and B). The 
proportion of  positive samples and the level of  immu-
nopositivity in the epithelium were comparable between 
the surgery group, the conservatively treated, and non-
IBD controls (Table 3). In total, 83% (39 of  47) of  the 
samples that were Tryp-1 positive in the colon epithelium 
were also Tryp-2 positive.
TATI: TATI was only detected in the colon epithelium, 
the inflammatory cells of  the colon stroma being nega-
tive for TATI (Figure 2C and D). The proportion of  
TATI positive samples and the level of  immunopositiv-
ity were comparable between the surgery group and the 
conservative and non-IBD groups (Table 3). The immu-
nopositivity of  TATI did not relate to the expression of  
Tryp-1 or Tryp-2 (data not shown).
MMP-9: In the colon, MMP-9 was mainly found in the 
stromal inflammatory cells and positive staining was de-
tected in the epithelium (Figure 2E and F). The propor-
tion of  MMP-9 immunopositive samples and the level 
of  immunopositivity in both the inflammatory cells and 
the epithelium were similar for the surgery group and 
the conservative group (Table 3). When compared to 
non-IBD patients, the proportion and immunopositivity 
of  MMP-9 in the inflammatory cells was higher in the 
UC patients, but we detected no differences when con-
sidering the epithelial positivity (Table 3). There was no 
association between the expression of  MMP-9 and the 
expression of  Tryp-1, Tryp-2, or TATI (data not shown). 
Staining results in the ileal samples 
In 59% of  the ileal samples (available for 36 UC patients 
and 14 non-IBD controls), the epithelium was Tryp-1 
positive. Of  the inflammatory cells in the stroma, 33% 
were Tryp-1 positive. The comparative staining propor-
tions were 100% for Tryp-2 (positivity of  the epithelium 
and inflammatory cells), 82% for TATI (positivity of  the 
epithelium, inflammatory cells negative) and 28% and 
26% for MMP-9 (positivity of  the epithelium and of  the 
inflammatory cells of  the stroma, respectively). The pro-
portions of  positively stained samples for Tryp-1, Tryp-2, 
and TATI were comparable between the studied groups. 
All UC patients, regardless of  treatment outcome, had 
significantly more MMP-9 positivity in the ileal epithe-
lium than non-IBD patients (P = 0.005). The staining in-
tensities of  the studied markers were similar in all of  the 
study groups (data not shown).
Association between disease activity and 
immunohistochemistry
The immunopositivity of  MMP-9 in the inflammatory 
cells was positively associated with the grade of  inflam-
mation in the colon (95%CI: 0.22-0.62; P = 0.0002). 
However, there was no association with MMP-9 im-
munopositivity and the other markers of  active disease. 
The staining intensities of  the other markers in the epi-
thelium of  the colon or in the inflammatory cells of  the 
stroma did not associate with the initial disease severity 
at diagnosis, the grade of  inflammation at diagnosis, the 
endoscopic distribution of  the disease at diagnosis, or the 
presence of  backwash ileitis.
Laboratory markers
All of  the primary laboratory values in the surgery group 
and disease controls were comparable. The blood inflam-
matory markers (CRP, ESR, WBC) were significantly 
Figure 1  Immunohistochemistry for trypsinogen-1. A: Lack of immunopositivity for trypsinogen-1 (Tryp-1) in a colonic sample at the diagnosis of a pediatric patient 
with ulcerative colitis who was operated on two years after diagnosis (× 200); B: Immunopositivity for Tryp-1 in the colonic epithelial cells of a diagnostic tissue sample 
from a conservatively treated patient with seven years follow-up from the diagnosis (× 400).
A B
Tryp-1 Tryp-1
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higher and the albumin level lower in UC patients com-
pared to the non-IBD controls (data not shown).
DISCUSSION
The exact roles of  the active inflammation markers tryp-
sinogens, TATI, and MMP-9 have not been studied in 
pediatric UC patients in relation to the disease outcome. 
Therefore, we compared the immunohistochemical posi-
tivity of  Tryp-1, Tryp-2, TATI, and MMP-9 in diagnostic 
colonoscopic tissue samples from pediatric UC patients 
who required surgery with those of  conservatively treated 
patients and non-IBD controls.
For the first time serine proteases Tryp-1 and Tryp-2 
were demonstrated in the epithelium and in the inflam-
matory cells of  the colon and ileum and TATI was found 
in the epithelium of  the colon and ileum in pediatric UC 
patients. At the time of  the diagnosis, the immunoposi-
tivity of  Tryp-1 in the colon epithelium is lower when 
comparing patients that have aggressive disease requiring 
surgery with those who have conservative treatment. We 
could also confirm that MMP-9 expression correlated 
with the grade of  inflammation of  the colon similarly, as 
reported earlier in adult and pediatric IBD patients[12].
Trypsinogens in pediatric UC
It is known that serine proteases regulate the gut barrier 
and inflammation cascade[14], and that they also take part 
in protease-activated receptor signaling, which has been 
shown to activate intestinal inflammation[29]. Thus, our 
finding of  a low Tryp-1 level in the colon epithelium of  
the surgery group is important because as many as 75% 
of  the patients had more than mild inflammation and 
nearly half  had acute severe disease at the time of  diag-
A B
C D
E F
Figure 2  Trypsinogen-2 was stained in the epithelium. A: Immunopositivity for trypsinogen-2 (Tryp-2); B: Immunonegativity for Tryp-2; C: Immunopositivity for 
tumor associated trypsin inhibitor (TATI); D: Immunonegativity for TATI; E: Immunopositivity for matrix metalloproteinase-9 (MMP-9); F: Immunonegativity for MMP-9. 
Arrows (A, E): Immunopositivity in the stromal inflammatory cells; Arrowheads (A, C, E): Immunopositivity in the epithelial cells. A-F, × 400. 
Tryp-2 Tryp-2 (neg)
TATI TATI (neg)
MMP-9 MMP-9 (neg)
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nosis. Acute inflammation is, however, not the only back-
ground factor explaining the low expression of  Tryp-1 in 
patients undergoing surgery; in addition, the immunopos-
itivity did not associate with the degree of  inflammation 
at diagnosis. The expression of  Tryp-2 was also low in 
all of  the studied groups. These findings, when taken to-
gether, indicate that trypsinogens are weakly expressed in 
the colon and not upregulated by inflammation in UC pa-
tients. Since they are also expressed in the healthy colon, 
their role might be mainly physiological. It may be specu-
lated that severe inflammation suppresses the physiologi-
cal secretion rate of  Tryp-1 but not Tryp-2 and TATI. At 
the moment, however, the exact role of  trypsins Tryp-1 
and Tryp-2 in intestinal inflammation remains unknown.
Trypsin inhibitor TATI
In healthy subjects proteases are expressed in the GI 
tract at low concentrations. An increase in concentrations 
is regarded as destructive; thus the balance between the 
proteases and their inhibitors is considered important[14]. 
It is known that TATI inhibits both Tryp-1 and Tryp-2 
equally[21]. We found no correlation between the expres-
sion of  the major trypsin inhibitor TATI and trypsino-
gens. Since the expression of  TATI was low, the weak 
expression of  trypsinogens could not be explained by 
the upregulation of  TATI. The low expression of  TATI 
in pediatric UC patients is in line with earlier findings 
showing reduced intestinal TATI in IBD and other GI 
conditions associated with abnormalities in the internal 
mucous layer[30]. However, as TATI and trypsinogens 
were also expressed in healthy colon, their low expression 
might be physiological.
MMP-9 association with trypsinogens
This study reports for the first time together the expres-
sion of  MMP-9 and trypsinogens in pediatric UC patients. 
However, the immunopositivity of  MMP-9 had no asso-
ciation with that of  Tryp-1 or Tryp-2. However, the small 
sample size in the present study has to be considered, 
and this finding does not either contradict or support the 
earlier report that trypsins associate with proMMP-9[16-19]. 
MMP-9 is expressed in the neutrophils but not in the co-
lon epithelium in pediatric IBD[31]. In the present study we 
showed, in addition to the upregulated MMP-9 expression 
in the inflammatory cells, epithelial immunopositivity for 
MMP-9 as well. This may be a novel finding as we vali-
dated our staining with care to avoid any unspecific stain-
ing reactivity. Of  the MMP inhibitors (TIMPs), TIMP-3 is 
expressed in pediatric IBD[14,30,32,33], and it correlates with 
the degree of  inflammation[30]. Unfortunately, the TIMP 
levels could not be assessed in this study. 
Strengths and limitations of the study
The aim of  the study was to compare two pediatric UC 
groups: those who would undergo surgery during child-
hood or adolescence and patients whose disease course 
is more benign. Although the patient population in this 
study is quite small, one strength of  the study was that the 
patient age and disease extension at diagnosis were com-
parable. Also, the duration of  disease of  patients who had 
undergone surgery and the disease controls was matched. 
Restorative proctocolectomy was performed at a median 
of  2 years after diagnosis (median age 15 years), and all the 
patients were followed-up at least until that time. In total, 
the disease controls were followed up for a median of  6 
years and none of  them had undergone surgery during 
this time period. We also had control samples from non-
IBD children, which demonstrated the natural expression 
of  studied markers in non-inflammatory bowel disease. 
In terms of  the limitations of  the results, we could 
only use one method for assessing trypsinogens, TATI, 
and MMP-9 profiles because the biopsy samples were 
very small and did not allow further analysis. Using mo-
lecular biological methods such as reverse transcription-
polymerase chain reaction or Western blotting to analyze 
the expression of  the studied markers would have given 
more strength to the study. However, we had the unique 
possibility to study the diagnostic samples and relate the 
data to the disease course of  the patients. Furthermore, 
two investigators blinded to the patient data assessed the 
samples. The discovery of  a low Tryp-1 level related to 
an aggressive disease course is preliminary and was not 
related to the altered expression of  its major inhibitor, 
TATI. Thus, the physiological mechanisms underlying 
these findings require further studies.
In conclusion, significant proportions of  pediatric 
UC patients suffer from aggressive disease and require 
surgery. It is estimated that approximately one in four pe-
diatric patients undergo colectomy during the first decade 
after the diagnosis[2,3,34]. No change in the surgery rate 
has been seen between the years 1994 and 2007[35]. By 
current diagnostic modalities, it is impossible to foresee 
the disease outcome at the time of  the diagnosis of  UC, 
although an initial aggressive disease increases the risk 
of  colectomy[6]. We found the expression of  Tryp-1 to 
be weaker in the epithelial cells of  patients with aggres-
sive disease but the mechanism and significance of  that 
finding remained unclear. Therefore, there is a need for 
further investigations on Tryp-1 and other biomarkers to 
identify patients with aggressively proceeding UC.
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from aggressive disease and require surgery. It is estimated that approximately 
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after the diagnosis. No change in the surgery rate was observed between the 
years 1994 and 2007.
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By current diagnostic modalities, it is impossible to foresee the disease out-
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come at the time of the diagnosis of UC, even though an aggressive initial 
disease presentation increases the risk of colectomy. If it was possible to rec-
ognize an aggressive disease course by biomarkers in the early disease phase, 
such patients could be introduced to early immunosuppressive treatment aimed 
at improving the disease outcome. The role of matrix metalloproteinase-9 
(MMP-9) is scarcely reported in pediatric inflammatory bowel disease (IBD). 
Trypsinogens and a trypsin inhibitor (TATI) have not been studied at all in pedi-
atric UC patients. Accordingly, the authors hypothesized that the expression of 
such proteases would be associated with the severity of the course of the UC. 
The hypothesis was tested by comparing the results of immunohistochemical 
staining on the diagnostic biopsy material of pediatric patients who underwent 
surgery vs conservatively treated patients and subjects without inflammatory 
bowel disease.
Innovations and breakthroughs
For the first time, the presence of the serine proteases trypsinogen-1 (Tryp-1) 
and Tryp-2 was demonstrated in the epithelium and in the inflammatory cells of 
the colon and ileum in pediatric UC. Accordingly, this is the first study to describe 
the expression of their inhibitor, TATI, in the epithelium of the colon and in the il-
eum in pediatric UC patients. The authors found that at the time of the diagnosis, 
the immunopositivity of Tryp-1 in the colon epithelium is lower when comparing 
pediatric UC patients who have an aggressive disease course requiring surgery 
to those managed by non-operative treatment. The authors could also confirm 
that the expression of MMP-9 correlated with the grade of inflammation of the 
colon similarly, as reported earlier in adult and pediatric IBD patients.
Applications
By demonstrating the protease profile of the colon mucosa of pediatric patients 
who will suffer from aggressive UC, this study may aid experts in characterizing 
the molecular environment of aggressive UC. The final goal is to find clinically 
applicable biomarkers for an aggressive disease.
Terminology
UC is a chronic inflammatory disease of the colon and the rectum that is of 
unknown origin; it is characterized by bloody diarrhea, abdominal pain, and 
weight loss; MMP, a family of 24 zinc-dependent enzymes, comprise a group 
of proteinases that degrade the extracellular matrix and basement membrane 
proteins in tissue remodeling processes both in normal and in pathological con-
ditions; Tryps are serine proteases that are capable of degrading extracellular 
matrix proteins and the pro-forms of acute phase reaction proteins, such as 
tumor necrosis factor, which cause damage to the mucosal barrier and UC-like 
inflammation. Tumor associated TATI inhibits trypsin in a 1:1 molar ratio.
Peer review
This is an interesting study delineating the colonic expression of key proteases 
in the setting of paediatric UC.
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